Last reviewed 2026-04-23 · How we verify

LBVH0101 (Hib vaccine)

LBVH0101 is a Haemophilus influenzae type b (Hib) conjugate vaccine that stimulates the immune system to produce antibodies against Hib polysaccharide capsule.

LBVH0101 is a Haemophilus influenzae type b (Hib) conjugate vaccine that stimulates the immune system to produce antibodies against Hib polysaccharide capsule. Used for Prevention of invasive Haemophilus influenzae type b disease (meningitis, bacteremia, epiglottitis).

At a glance

Mechanism of action

The vaccine contains purified Hib polyribosyl ribitol phosphate (PRP) polysaccharide conjugated to a protein carrier, which enhances immunogenicity and T-cell dependent immune response. This allows the vaccine to induce both humoral and cellular immunity, providing protection against invasive Hib disease including meningitis, bacteremia, and epiglottitis.

Approved indications

• Prevention of invasive Haemophilus influenzae type b disease (meningitis, bacteremia, epiglottitis)

Common side effects

• Injection site reactions (pain, redness, swelling)
• Fever
• Irritability
• Drowsiness

Key clinical trials

• Immunogenicity and Safety Study of 4th LBVH0101 After the Primary Vaccination in LG-VHCL002 Study (PHASE3)
• Immunogenicity and Safety Study of LBVH0101 in Healthy Infants at Two, Four and Six Months of Age (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• LBVH0101 (Hib vaccine) CI brief — competitive landscape report
• LBVH0101 (Hib vaccine) updates RSS · CI watch RSS
• LG Life Sciences portfolio CI